Non-viral gene therapy for diabetic retinopathy

Drug Development Research

Volumn 67, Issue 11, 2006, Pages 835-841

  Oshitari, Toshiyuki ^a,b,c  

^a Sannoh Medical Center   (Japan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Antisense oligonucleotides; Diabetic retinopathy; Extracellular matrix; Neurovascular abnormalities; Non viral gene therapy; Small interference RNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FOMIVIRSEN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; SMALL INTERFERING RNA;

BLOOD VESSEL PERMEABILITY; DIABETIC RETINOPATHY; DISEASE COURSE; ELECTROPORATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROLOGICAL COMPLICATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; RETINA BLOOD VESSEL; RETINITIS; REVIEW; RNA INTERFERENCE; SYSTEMATIC REVIEW; TREATMENT INDICATION; VASCULAR DISEASE;

EID: 33846975039     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20157     Document Type: Review

References (78)

1. Aizu Y, Katayama H, Takahama S, Hu J, Nakagawa H, Oyanagi K. 2003. Topical instillation of ciliary neurotrpphic factor inhibits retinal degeneration in streptozotocin-induced diabetic rats. Neuroreport 14:2067-2071.
2. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. 1997. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 38:36-47.
3. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. 2003. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 52:506-511.
4. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. 2006. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372.
5. Barber AJ. 2003. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 27:283-290.
6. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. 1998. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783-791.
7. Baum C, Dullmann J, Li Z, Fehse B, Meyer J, Williams DA, von Kalle C. 2003. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101:2099-2114.
8. Becker D, Meier CB, Herlyn M. 1989. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 8:3685-3691.
9. Billy E, Brondani V, Zhang H, Müller U, Filipowicz W 2001. Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. Proc Natl Acad Sci USA 98:14428-14433.
10. Böcker-Meffert S, Rosenstiel P, Rohl C, Warneke N, Held-Feindt J, Sievers J, Lucius R. 2002. Erythropoietin and VEGF promote neural outgrowth from retinal explants in postnatal rats. Invest Ophthalmol Vis Sci 43:2021-2026.
11. Brockington A, Lewis C, Wharton S, Shaw PJ. 2004. Vascular endothelial growth factor and the nervous system. Neuropathol Applied Neurobiol 30:427-446.
12. Cheng L, Chaidhawangul S, Wong-Staal F, Gilbert J, Poeschla E, Toyoguchi M, El-Bradey M, Bergeron-Lynn G, Soules KA, Freeman WR. 2002. Human immunodeficiency virus type 2 (HIV-2) vector-mediated in vivo gene transfer into adult rabbit retina. Curr Eye Res 24:196-201.
13. Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF. 1991. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 266:18162-18171.
14. Crooke ST. 2004. Antisense strategies. Curr Mol Med 4:465-487.
15. Curds TM, McKeown-Longo PJ, Vincent PA, Homan SM, Wheatley EM, SabaTM. 1995. Fibronectin attenuates increased endothelial monolayer permeability after RGD peptide, anti-alpha 5 beta 1, or TNF-alpha exposure. Am J Physiol 269:L248-L260.
16. Das A, Frank RN, Zhang NL, Samadani E. 1990. Increase in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening-prevention by an aldose reductase inhibitor. Exp Eye Res 50:269-280.
17. Dezawa M, Takano M, Negishi H, Mo X, Oshitari T, Sawada H. 2002. Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach. Micron 33:1-6.
18. Doganay S, Evereklioglu C, Er H, Turkoz Y, Sevinc A, Mehmet N, Savli H. 2002. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16:163-170.
19. Dudus L, Anand V, Acland GM, Chen SJ, Wilson JM, Fisher KJ, Maguire AM, Bennett J. 1999. Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV Vision Res 39:2545-2553.
20. Easton RM, Johnson EM, Creedon DJ. 1998. Analysis of events leading to neuronal death after infection with E1-deficient adenoviral vectors. Mol Cell Neurosci 11:334-347.
21. Elbashir SM, Harborth J, Lendeckel W, Yelcin A, Weber K, Tuschl T. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.
22. Elbashir SM, Harborth J, Weber K, Tuschl T. 2002. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 26:199-213.
23. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. 2003. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 162:1995-2004.
24. Hammond SM, Bernstein E, Beach D, Hannon GJ. 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404:293-296.
25. Hennig AK, Levy B, Ogilvie JM, Vogler CA, Galvin N, Bassnett S, Sands MS. 2003. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J Neurosci 23:3302-3307.
26. Hutvagner G, Zamore PD. 2002. A microRNA in a multiple-turnover RNAi enzyme complex. Science 297:2056-2060.
27. Isenmann S, Engel S, Gillardon F, Bähr M. 1999. Bax antisense oligonucleotides reduce axotomy-induced retinal ganglion cell death in vivo by reduction of Bax protein expression. Cell Death Differ 6:673-682.
28. Ishida S, Shinoda K, Kawashima S, Oguchi Y, Okada Y, Ikeda E. 2000. Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 41:1649-1656.
29. Ishikawa H, Takano M, Matsumoto N, Sawada H, Ide C, Mimura O, Dezawa M. 2005. Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. Gene Ther 12:289-298.
30. Jabs DA, Griffiths PD. 2002. Fomivirsen for the treatment of cytomegalovirus retinitis. Am J Ophthalmol 133:552-556.
31. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP. 2002. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 16:438-440.
32. Kabanov AV, Vinogradov SV, Suzdaltseva YG, Alakhov VYu. 1995. Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjug Chem 6:639-643.
33. Lehrman S. 1999. Virus treatment questioned after gene therapy death. Nature 401:517-518.
34. Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, Forster M, Stocking C, Wahlers A, Frank O, Ostertag W, Kuhlcke K, Eckert HG, Fehse B, Baum C. 2002. Murine leukemia induced by retroviral gene marking. Science 296:497.
35. Lisovoski F, Akli S, Peltekian E, Vigne E, Haase G, Perricaudet M, Dreyfus PA, Kahn A, Peschanski M. 1997. Phenotypic alteration of astrocytes induced by ciliary neurotrophic factor in the intact adult brain, As revealed by adenovirus-mediated gene transfer. J Neurosci 17:7228-7236.
36. Lorenzi M, Gerhardinger C. 2001. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia 44: 791-804.
37. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP. 1998. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101:1219-1224.
38. Luke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T, Luke C, Partsch M, Bartz-Schmidt KU, Szurman P. 2006. Effects of bevacizumab ((R)) on retinal function in isolated vertebrate retina. Br J Ophthalmol 90:1178-1182.
39. Mandarino LJ, Sundarraj N, Finlayson J, Hassell HR. 1993. Regulation of fibronectin and laminin synthesis by retinal capillary endothelial cells and pericytes in vitro. Exp Eye Res 57:609-621.
40. Martinez J, Patkaniowska A, Urlaub H, Lührmann R, Tuschl T. 2002. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110:563-574.
41. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. 2005. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112: 1035-1047.
42. Mo X, Yokoyama A, Oshitari T, Negishi H, Dezawa M, Mizota A, Adachi-Usami E. 2002. Rescue of axotomized retinal ganglion cells by BDNF gene electroporation in adult rats. Invest Ophthalmol Vis Sci 43:2401-2405.
43. Mori K, Gehlbach P, Ando A, Wahlin K, Gunther V McVey D, Wei L, Campochiaro PA. 2002. Intraocular adenoviral vector-mediated gene transfer in proliferative retmopathies.Invest Ophthalmol Vis Sci 43:1610-1615.
44. Mourelatos Z, Dosite J, Paushkin S, Sharma A, Charroux B, Abel L, Rappsilber J, Mann M, Dreyfuss G. 2002. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Genes Dev 16:720-728.
45. Nagel KM, Holstad SG, Isenberg KE. 1993. Oligonucleotide pharmacotherapy: an antigene strategy. Pharmacotherapy 13:177-188.
46. Nykänen A, Haley B, Zamore PD. 2001. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107:309-321.
47. Oshitari T, Adachi-Usami E. 2003. The effect of caspase inhibitors and neurotrophic factors on damaged retinal ganglion cells. Neuroreport 14:289-292.
48. Oshitari T, Roy S. 2005. Diabetes: a potential enhancer of retinal injury in rat retinas. Neurosci Lett 390:25-30.
49. Oshitari T, Dezawa M, Okada S, Takano M, Negishi H, Horie H, Sawada H, Tokuhisa T, Adachi-Usami E. 2002a. The role of c-fos in cell death and regeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci 43:2442-2449.
50. Oshitari T, Fujimoto N, Adachi-Usami E. 2002b. Citicoline has a protective effect on damaged retinal ganglion cells in mouse culture retina. Neuroreport 13:2109-2111.
51. Oshitari T, Okada S, Tokuhisa T, Adachi-Usami E. 2003. Adenovirus-mediated gene transfer of Bcl-xL impedes neurite regeneration in vitro. Neuroreport 14:1159-1162.
52. Oshitari T, Brown D, Roy S. 2005. SiRNA strategy against overexpression of extracellular matrix in diabetic retinopathy. Exp Eye Res 81:32-37.
53. Oshitari T, Polewski P, Chadda M, Li AF, Sato T, Roy S. 2006. Effect of combined antisense oligonucleotides against high-glucose- and diabetes-induced overexpression of extracellular matrix components and increased vascular permeability. Diabetes 55:86-92.
54. Osterby R. 1990. Basement membrane morphology in diabetes mellitus. In: Rifkin HP, Porte D Jr., editors. Diabetes mellitus: theory and practice. New York: Elsevier Science. p. 220-233.
55. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. 2002. Short hairpin RNAs (shRNA) induce sequence-specific silencing in mammalian cells. Genes Dev 16:948-958.
56. Partridge CA, Horvath CJ, Del Vecchio PJ, Phillips PG, Malik AB. 1992. Influence of extracellular matrix in tumor necrosis factor-induced increase in endothelial permeability. Am J Physiol 263: L627-L633.
57. Podesta F, Romeo G, Liu WH, Krajewski S, Reed JC, Gerhardinger C, Lorenzi M. 2000. Bax is increased in the retina of diabetic subjects and is associated with pericyte apoptosis in vivo and in vitro. Am J Pathol 156:1025-1032.
58. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. 2001. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408-2413.
59. Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ. 2003. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9:210-216.
60. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M. 2002. Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. Diabetes 51:2241-2248.
61. Rosenfeld PJ, Fung AE, Puliafito CA. 2005. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imag 36:336-339.
62. Roy S, Zhang K, Roth T, Vinogradov S, Kabanov A. 1999. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides in rat retina. Nature Biotechnol 17:476-479.
63. Roy S, Sato T, Paryani G, Kao R. 2003. Downregulation of fibronectin overexpression reduces basement membrane thickening and vascular lesions in retinas of galactose-fed rats. Diabetes 52:1229-1234.
64. Sato T, Paryani G, Kao RS, Li AF, Roy S. 2001. Antisense oligonucleotides modulate high glucose-induced laminin overexpression and cell proliferation: a potential for therapeutic application in diabetic microangiopathy. Antisense Nucleic Acid Drug Dev 11:387-394.
65. Seki M, Tanaka T, Nawa H, Usui T, Fukuchi T, Ikeda K, Abe H, Takei N. 2004. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53:2412-2419.
66. Shweiki D, Itin A, Soffer D, Keshet E. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845.
67. Spencer B, Agarwala S, Miskulin M, Smith M, Brandt CR. 2000. Herpes simplex virus-mediated gene delivery to the rodent visual system. Invest Ophthalmol Vis Sci 41:1392-1401.
68. Stein CA, Cheng YC. 1993. Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science 261:1004-1012.
69. Takano M, Sango K, Horie H, Sato M, Iijima Y, Ohno S, Inoue S, Ishikawa Y. 1999. Diabetes alters neurite regeneration from mouse retinal explants in culture. Neurosci Lett 275:175-178.
70. Takano M, Horie H, Iijima Y, Dezawa M, Sawada H, Ishikawa Y. 2002. Brain-derived neurotrophic factor enhances neurite regeneration from retinal ganglion cells in aged human retina in vitro. Exp Eye Res 74:319-323.
71. Tezel G, Li LY, Patil RV, Wax MB. 2001. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 42:1787-1794.
72. Thomas CE, Birkett D, Anozie I, Castro MG, Lowenstein PR. 2001. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 3:36-46.
73. Vickers T, Baker BF, Cook PD, Zounes M, Buckheit RW Jr, Germany J, Ecker DJ. 1991. Inhibition of HIV-LTR gene expression by oligonucleotides targeted to the TAR element. Nucleic Acids Res 19:3359-3368.
74. Vitravene Study Group. 2002a. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 133:467-474.
75. Vitravene Study Group. 2002b. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol 133:475-483.
76. Vitravene Study Group. 2002c. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 133:484-498.
77. Weber M, Rabinowitz J, Provost N, Conrath H, Folliot S, Briot D, Cherel Y, Chenuaud P, Samulski J, Moullier P, Rolling F. 2003. Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol Ther 7:774-781.
78. Yokoyama A, Oshitari T, Negishi H, Dezawa M, Mizota A, Adachi-Usami E. 2001. Protection of retinal ganglion cells from ischemia-reperfusion injury by electrically applied Hsp27. Invest Ophthalmol Vis Sci 42:3283-3286.